The seventh edition of the non-small cell lung cancer (NSCLC) TNM staging system was
developed by the International Association for the Staging of Lung Cancer (IASLC) Lung …

Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant
therapy guideline for resected non–small-cell lung cancers. Methods ASCO convened an …

The molecular underpinnings that drive the heterogeneity of KRAS-mutant lung
adenocarcinoma are poorly characterized. We performed an integrative analysis of …

Importance The prevalence of early-stage non–small cell lung cancer (NSCLC) is expected
to increase with recent implementation of annual screening programs. Reliable prognostic …

In the last decade, optimized treatment for non-small cell lung cancer had lead to improved
prognosis, but the overall survival is still very short. To further understand the molecular …

Background The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients
with good or low surgical risk is primarily surgical resection. However, this area is …

Validation of multi-gene biomarkers for clinical outcomes is one of the most important issues
for cancer prognosis. An important source of information for virtual validation is the high …

Non-small cell lung cancer (NSCLC) accounts for> 80% of lung cancer cases and currently
has an overall five-year survival rate of only 15%. Patients presenting with advanced stage …

Purpose To detect a pretreatment gene expression signature (GS) predictive of response to
MAGE-A3 immunotherapeutic in patients with metastatic melanoma and to investigate its …

Background Lung adenocarcinomas (LUAD) is the most common histological subtype of
lung cancers. Tumor immune microenvironment (TIME) is involved in tumorigeneses …